Clinical trials: Bladder Tumors
Bladder Cancer
Determinants of Bladder Cancer Recurrence Study (The DETER Study)
The purpose of this study is to learn how different lifestyle factors, such as cigarette smoking and body weight, change after a diagnosis of bladder cancer, and how they influence who gets a bladder cancer recurrence and who…
- Trial name
- NCT02400944
- Testing
- questionnaires, Saliva and/or urine sample
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer Patients Candidate for Radical Cystectomy
Preoperative Subclinical DVT Screening in Locally Advanced Bladder Cancer Patients Candidate for Radical Cystectomy.
Preoperative subclinical DVT screening in locally advanced bladder cancer patients candidate for radical cystectomy.
- Trial name
- NCT04502498
- Testing
- Lower limb duplex & doppler
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Bladder Cancer
Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the imaging of Non-muscle-invasive bladder cancer…
- Trial name
- PERTINENCE (NCT04897763)
- Testing
- 89Zr-TLX250
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Institut Cancerologie de l'Ouest
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of pembrolizumab, when given as a single agent in patients with bladder tumors.
- Conditions
- Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
- Trial name
- NCT02808143
- Testing
- BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Bladder Cancer, Hematuria; Benign
PENK Methylation Test for Detecting Bladder Cancer
The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® Bladder Cancer test for bladder cancer among patients with hematuria by comparing it to the results of cystoscopy…
- Trial name
- NCT05220189
- Testing
- EarlyTect® Bladder Cancer test
- Where
- South Korea
- Volunteers
- 1,549 people
- Sponsor
- Asan Medical Center
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Neoplasms, Malignancies
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used.
- Trial name
- NCT02257476
- Testing
- Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Bladder Cancer, Recurrence
Photodynamic Diagnosis (PDD) in Flexible Cystoscopy
Photodynamic diagnostic (PDD) is a technique where a photodynamic drug is installed preoperatively in the bladder. Mucosa cells with a higher metabolism than normal urothelial cells, e.g.
- Conditions
- Bladder Cancer, Recurrence, PDD
- Trial name
- DaBlaCa-11 (NCT02660190)
- Testing
- hexaminoavolunate, WL cystoscopy
- Where
- 2 sites in Denmark
- Volunteers
- 696 people
- Sponsor
- Jørgen Bjerggaard Jensen
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
- Trial name
- ACTICCA-1 (NCT02170090)
- Testing
- Gemcitabine, Cisplatin, Capecitabine
- Where
- 67 sites in Australia, Austria and 6 more
- Volunteers
- 789 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Intermediate or High-risk Bladder Cancer
Hexvix Photodynamic Therapy in Patients With Bladder Cancer
The purpose of the study is to investigate the safety and feasibility of Hexaminolevulinate based photodynamic therapy in patients with intermediate or high-risk transitional cell carcinoma of the bladder.
- Trial name
- NCT01303991
- Testing
- Hexvix PDT with Karl Storz T-Light
- Volunteers
- 17 people
- Sponsor
- Photocure
Bladder Cancer
Lymph Node Dissection Before or After Cystectomy
The purpose of this study is to compare different ways of performing surgery for bladder cancer. Specifically, the goal is to determine whether it is better to remove the lymph nodes before removing the bladder or after removing…
- Trial name
- LBOACP (NCT05939856)
- Testing
- Lymph node dissection before bladder resection, Lymph node dissection after bladder resection
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Jagiellonian University
Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Bladder cancer is the 4th most common cancer amongst men. If bladder cancer invades the muscle of the bladder or fails local treatments, surgical removal of the bladder (cystectomy) with creation of a new bladder from intestine…
- Trial name
- SPARC (NCT01824329)
- Testing
- Prostate capsule sparing cystectomy, Nerve sparing cystectomy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder.
- Conditions
- Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT00072137
- Testing
- Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Bladder Cancer
Bio Clinical Collection of Urothelial Carcinoma
The goal of this study is to collect tumor samples, urines, stool and blood from patients with urothelial carcinoma. These samples will be stored in a secure and confidential laboratory of the Toulouse University Hospital.
- Trial name
- MicroBlad (NCT04970472)
- Testing
- collection of blood, urines, stool and tumor samples
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Toulouse
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002684
- Testing
- cisplatin, ifosfamide, paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-muscle Invasive Bladder Cancer
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
To determine the efficacy of oral APL-1202 administered consecutively for 12 weeks in subjects with high-risk NMIBC relapsed from intravesical chemo/BCG therapy based on the recurrence-free rate (RFR) at 12 months after APL-1202…
- Trial name
- NCT04498702
- Testing
- APL-1202 treatment
- Volunteers
- 41 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.